Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

 Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 150 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 475 basis points.
September 11, 2026

Vinge advises IK Partners and Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik

 Vinge has advised IK Partners and its portfolio company Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik, a company specialising in refrigeration technology and refrigeration services in southern Sweden. The acquisition strengthens Francks Kylindustri’s position in southern Sweden and broadens the group’s offering within the refrigeration industry.
September 11, 2026

Vinge advises the sellers of Berg Propulsion

 Vinge has advised the sellers in connection with the sale of Berg Propulsion to Kongsberg Maritime.
September 10, 2026